Therapeutic strategies towards HIV-1 infection in macrophages

Antiviral Research

Volumn 71, Issue 2-3 SPEC. ISS., 2006, Pages 293-300

  Perno, Carlo Federico ^a   Svicher, Valentina ^b   Schols, Dominique ^c   Pollicita, Michela ^b   Balzarini, Jan ^c   Aquaro, Stefano ^b,d  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^d UNIVERSITY OF CALABRIA   (Italy)

Author keywords

Antiretroviral drugs; CD4+ lymphocytes; HIV 1; Macrophages

Indexed keywords

ABACAVIR; ACYCLIC NUCLEOSIDE; AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; APLAVIROC; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; GLYCOPROTEIN GP 120[185-192]; INDINAVIR; LAMIVUDINE; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; NELFINAVIR; NEVIRAPINE; PHOSPHONIC ACID DERIVATIVE; PLANT LECTIN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; SYNTHETIC PEPTIDE; TENOFOVIR; UK 247 857; UK 427 857; UNCLASSIFIED DRUG; VICRIVIROC; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACROPHAGE; PHOSPHORYLATION; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT OUTCOME; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; HIV INFECTIONS; HIV-1; HUMANS; MACROPHAGES; PLANT LECTINS; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33747105507     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.05.015     Document Type: Short Survey

References (74)

1. Ahluwalia G., Cooney D.A., Mitsuya H., Fridland A., Flora K.P., Hao Z., Dalal M., Broder S., and Johns D.G. Initial studies on the cellular pharmacology of 2′,3′-dideoxyinosine, an inhibitor of HIV infectivity. Biochem. Pharmacol. 36 (1987) 3797-3801
2. Alkhatib G., Combadiere C., Broder C.C., Feng Y., Kennedy P.E., Murphy P.M., and Berger E.A. CC, CKR5: a RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272 (1996) 1955-1958
3. Aquaro S., Bagnarelli P., Guenci T., De Luca A., Clementi M., Balestra E., Caliò R., and Perno C.F. Long-term survival and virus production in human primary macrophages infected by human immunodeficiency virus. J. Med. Virol. 68 (2002) 479-488
4. Aquaro S., Caliò R., Balestra E., Bagnarelli P., Cenci A., Bertoli A., Tavazzi B., Di Pierro D., Francesconi M., Abdelahad D., and Perno C.F. Clinical implications of HIV dynamics and drug resistance in macrophages. J. Biol. Regul. Homeost. Agents 12 (1998) 23-27
5. Aquaro S., Guenci T., Di Santo F., Francesconi M., Caliò R., and Perno C.F. Potent antiviral activity of amprenavir in primary macrophages infected by human immunodeficiency virus. Antiviral Res. 61 (2004) 133-137
6. Aquaro S., Menten P., Struyf S., Proost P., Van Damme J., De Clercq E., and Schols D. The LD78_ isoform of MIP-1α is the most potent CC-chemokine in inhibiting CCR5-dependent HIV-1 replication in human macrophages. J. Virol. 75 (2001) 4402-4406
7. Aquaro S., Panti S., Caroleo M.C., Balestra E., Cenci A., Forbici F., Ippolito G., Mastino A., Testi R., Mollace V., Caliò R., and Perno C.F. Primary macrophages infected by human immunodeficiency virus trigger CD95-mediated apoptosis of uninfected astrocytes. J. Leukocyte Biol. 68 (2000) 429-435
8. Aquaro S., Perno C.F., Balestra E., Balzarini J., Cenci A., Francesconi M., Panti S., Serra F., Villani N., and Caliò R. Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes. J. Leukocyte Biol. 62 (1997) 138-143
9. Aquaro S., Wedgwood O., Yarnold C., Cahard D., Pathinara R., McGuigan C., Calio' R., De Clercq E., Balzarini J., and Perno C.F. Activity of masked 2′,3′-dideoxynucleoside monophosphate derivatives against human immunodeficiency virus in resting macrophages. Antimicrob. Agents Chemother. 44 (2000) 173-177
10. Aquaro S., Svicher V., D'Arrigo R., Visco-Comandini U., Antinori A., Santoro M., Di Perri G., Lo Caputo S., Narciso P., and Perno C.F. Characterization of Gp41 evolution in a large cohort of HIV-1-infected patients receiving long-term T-20 treatment as a single active drug. 13th Conference on Retroviruses and Opportunistic Infection. Denver, February 5-8 (2006)
11. Baba M., Nishimura O., Kanzaki N., Okamoto M., Sawada H., Iizawa Y., Shiraishi M., Aramaki Y., Okonogi K., Ogawa Y., Meguro K., and Fujino M. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 5698-5703
12. Badley A.D., Dockrell D., Simpson M., Schut R., Lynch D.H., Leibson P., and Paya C.V. Macrophage-dependent apoptosis of CD4+ T lymphocytes from HIV-infected individuals is mediated by FasL and tumor necrosis factor. J. Exp. Med. 185 (1997) 55-64
13. Bagnarelli P., Valenza A., Menzo S., Sampaolesi R., Varaldo P.E., Butini L., Montoni M., Perno C.F., Aquaro S., Mathez D., Leibowitch J., Balotta C., and Clementi M. Dynamics and modulation of human immunodeficiency virus type 1 transcripts in vitro and in vivo. J. Virol. 70 (1996) 7603-7613
14. Balzarini J. Targeting the glycans of gp120: a novel therapeutic approach aimed at the Achilles heel of HIV. Lancet 5 (2005) 726-731
15. Balzarini J., Aquaro S., Knispel T., Ramazzo C., Bianchi V., Perno C.F., De Clercq E., and Meier C. CycloSaligenyl-2′,3′-didehydro-2′,3′-dideoxythymidine monophosphate (CycloSal-d4TMP): efficient intracellular delivery of d4TMP. Mol. Pharmacol. 58 (2000) 928-935
16. Balzarini J., Aquaro S., Perno C.F., Witvrouw M., Holy A., and De Clercq E. Activity of the (R)-enantiomers of 9-(2-phosphonylmethoxypropyl)adenine and 9-(2-phosphonylmethoxypropyl)-2-6-diaminopurine against human immunodeficiency virus in different human cell systems. Biochem. Biophys. Res. Commun. 219 (1996) 337-341
17. Balzarini J., Karlsson A., Aquaro S., Perno C.F., Canard D., Naesens L., De Clercq E., and McGuigan C. Mechanism of anti-HIV action of masked alaninyl d4T-MP derivatives. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 7295-7299
18. Balzarini J., Baba M., Pauwels R., Herdewijn P., and De Clercq E. Anti-retrovirus activity of 3′-fluoro- and 3′-azidosubstituted pyrimidine 2′,3′-dideoxynucleoside analogues. Biochem. Pharmacol. 37 (1988) 2847-2856
19. Balzarini J., Hatse S., Vermeire K., Princen K., Aquaro S., Perno C.F., De Clercq E., Egberink H., Vanden Mooter G., Peumans W., Van Damme E., and Schols D. Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection. Antimicrob. Agents Chemother. 48 (2004) 3858-3870
20. Balzarini J., Herdewijn P., and De Clercq E. Differential patterns of intracellular metabolism of 2′,3′-didehydro-2′,3′-dideoxythymidine and 3′-azido-2′,3′-dideoxythymidine, two potent anti-humanimmunodeficiency virus compounds. J. Biol. Chem. 264 (1989) 6127-6133
21. Balzarini J., Kang G.J., Dalal M., Herdewijn P., De Clercq E., Broder S., and Johns D.G. The anti-HTLV-III (anti-HIV) and cytotoxic activity of 2′,3′-didehydro-2′,3′-dideoxyribonucleosides: a comparison with their parental 2′,3′-dideoxyribonucleosides. Mol. Pharmacol. 32 (1987) 162-167
22. Balzarini J., Naesens L., Aquaro S., Knispel T., Perno C.F., De Clercq E., and Meier C. Intracellular metabolism of cyclosaligen 3′-azido-2′,3′-dideoxythymidine monophosphate, a prodrug of 3_-azido-2′,3′-dideoxythymidine (zidovudine). Mol. Pharmacol. 56 (1999) 1354-1361
23. Balzarini J., Van Laethem K., Hatse S., Froeyen M., Peumans W., Van Damme E., and Schols D. Carbohydrate-binding agents cause deletions of highly conserved glycosylation sites in HIV GP120 A new therapeutic concept to hit the Achilles heel of HIV. J. Biol. Chem. 280 (2005) 41005-41014
24. Cocchi F., De Vico A.L., Garzino-Demo A., Arya S.K., Gallo R.C., and Lusso P. Identification of RANTES, MIP-1alpha, and MIP-1beta major HIV-suppressive factors produced by CD8+ T cells. Science 270 (1995) 1811-1815
25. Crowe S.M., Mills J., Kirihara J., Boothman J., Marshall J.A., and Mc Grath M.S. Full-length recombinant CD4 and recombinant gp120 inhibit fusion between HIV infected macrophages and uninfected CD4-expressing T-lymphoblastoid cells. AIDS Res. Hum. Retrovir. 6 (1990) 1031-1037
26. De Clercq E., Holy A., Rosemberg I., Sakuma T., Balzarini J., and Maudgal P.C. A novel selective broad-spectrum anti-DNA agent. Nature 323 (1986) 464-467
27. De Clercq E., Sacuma T., Baba M., Pauwels R., Balzarini J., Rasemberg I., and Holy A. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res. 8 (1987) 261-272
28. Dorr P., Westby M., Dobbs S., Griffin P., Irvine B., Macatney M., Mori J., Rickett G., Smith-Burchnell C., Napier C., Webster R., Armour D., Price D., Stammen B., Wood A., and Perros M. Maraviroc (UK-427,857), a potent, orally bioavailable and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49 (2005) 4721-4732
29. Dragic T., Trkola A., Thompson D.A., Cormier E.G., Kajumo E.A., Maxwell E., Lin S.W., Ying W., Smith S.O., Sakmar T.P., and Moore J.P. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 5639-5644
30. Gabuzda D.H., Ho D.D., de la Monte S.M., Hirsch M.S., Rota T.R., and Sobel R.A. Immunohistochemical identification of HTLV-III antigen in brains of patients with AIDS. Ann. Neurol. 20 (1986) 289-295
31. Garaci E., Aquaro S., Lapenta C., Amendola A., Spada M., Covaceuszach S., Perno C.F., and Belardelli F. Anti-nerve growth factor Ab abrogates macrophage-mediated HIV-1 infection and depletion of CD4+ T lymphocytes in hu-SCID mice. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 8927-8932
32. Garaci E., Caroleo M.C., Aloe L., Aquaro S., Piacentini M., Costa N., Amendola A., Miera A., Caliò R., Perno C.F., and Levi-Montalcini R. Nerve growth factor is an autocrine factor essential for the survival of macrophages infected with HIV. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 14013-14018
33. Gartner S., Markovits P., Markovitz D.M., Kaplan M.H., Gallo R.C., and Popovic M. The role of mononuclear phagocytes in HTLVIII/LAV infection. Science 233 (1986) 215-219
34. Gendelman H.E., Orenstein J.M., Martin M.A., Ferrua C., Mitra R., Phipps T., Walh L.A., Lane H.C., Fauci A.S., Burke D.S., Skillman D., and Meltzer M.S. Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J. Exp. Med. 167 (1988) 1428-1441
35. Hao Z., Cooney D.A., Farquhar D., Perno C.F., Zhang K., Masood R., Wilson Y., Hartman N.R., Balzarini J., and Johns D.G. Potent DNA chain termination activity and selective inhibition of human immunodeficiency virus reverse transcriptase by 2′,3′-dideoxyuridine-5′-triphosphate. Mol. Pharmacol. 37 (1990) 157-163
36. Haworth S.J., Christofalo B., Anderson R.D., and Dunkle L.M. A single-dose study to assess the penetration of stavudine into human cerebrospinal fluid in adults. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 17 (1998) 235-238
37. Herbein G., Coaquette A., Perez-Bercoff D., and Pancino G. Macrophage activation and HIV infection: can the Trojan horse turn into a fortress?. Curr. Mol. Med. 2 (2002) 723-738
38. Herbein G., Mahlknecht U., Batliwalla F., Gregerson P., Pappas T., Butler J., O'Brein W.A., and Verdin E. Apoptosis of CD8+ T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4. Nature 395 (1998) 189-194
39. Johnson M.A., and Fridland A. Phosphorylation of 2′,3′-dideoxyinosine by cytosolic 5′-nucleotidase of human lymphoid cells. Mol. Pharmacol. 36 (1989) 291-295
40. Ketas T.J., Frank I., Klasse P.J., Sullivan B.M., Gardner J.P., Spenlehauer C., Nesin M., Olson W.C., Moore J.P., and Pope M. Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells. J. Virol. 77 (2003) 2762-2767
41. Kilby J.M., Lalezari J.P., Eron J.J., Carlson M., Cohen C., Arduino R.C., Goodgame J.C., Gallant J.E., Volberding P., Murphy R.L., Valentine F., Saag M.S., Nelson E.L., Sista P.R., and Dusek A. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS 18 (2002) 685-693
42. Koenig S., Gendelman H.E., Orenstein J.M., Dal Canto M.C., Pezeshkpour G.H., Yungbluth M., Janotta F., Aksamit A., Martin M.A., and Fauci A.S. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 233 (1986) 1089-1093
43. Lane J.H., Sasseville V.G., Smith M.O., Vogel P., Pauley D.R., Heyes M.P., and Lackner A.A. Neuroinvasion by simian immunodeficiency virus coincides with increased numbers of perivascular M/M/microglia and intrathecal immune activation. J. Neurovir. 2 (1996) 423-432
44. Lewis L.L., Venzon D., Church J., Farley M., Wheeler S., Keller A., Rubin M., Yuen G., Mueller B., Sloas M., Wood L., Balis F., Shearer G.M., Brouwers P., Goldsmith J., Pizzo P.A., and The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group. Lamivudine in children with human immunodeficiency virus infection: a phase I-II study. J. Infect. Dis. 174 (1996) 16-25
45. Lori F., and Lisziewicz J. Structured treatment interruptions for the management of HIV infection. J. Am. Med. Assoc. 286 (2001) 2981-2987
46. Malorni W., Lucia M.B., Rainaldi G., Cauda R., Cianfriglia M., Donelli G., and Ortona L. Intracellular expression of p170 glycoprotein in peripheral blood mononuclear cell subsets from healthy donors and HIV-infected patients. Haematologica 83 (1998) 13-20
47. McElrath M.J., Pruett J.E., and Cohn Z.A. Mononuclear phagocytes of blood and bone marrow: comparative roles as viral reservoirs in human immunodeficiency virus type 1 infections. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 675-679
48. Mollace V., Salvemini D., Riley D.P., Muscoli C., Inaccone M., Granato T., Masuelli L., Modesti A., Rotiroti D., Nisticò R., Bertoli A., Perno C.F., and Aquaro S. The contribution of oxidative stress in apoptosis of human cultured astroglial cells induced by supernatants of HIV-1 infected macrophages. J. Leukocyte Biol. 71 (2002) 65-72
49. Naesens L., Bischofberger N., Augustijns P., Annaert P., Van den Mooter G., Arimilli M.N., Kim C.U., and De Clercq E. Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxypropyl)adenine in mice. Antimicrob. Agents Chem. 42 (1998) 1568-1573
50. Orenstein J.M., Meltzer M.S., Phipps T., and Gendelman H.E. Cytoplasmic assembly and accumulation of human immunodeficiency virus types 1 and 2 in recombinant human colony-stimulating factor-1-treated human monocytes: an ultrastructural study. J. Virol. 62 (1988) 2578-2586
51. Ortiz G.M., Wellons M., Brancato J., Vo H.T., Zinn R.L., Clarkson D.E., Van Loon K., Bonhoeffer S., Miralles G.D., Montefiori D., Bartlett J.A., and Nixon D.F. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 13.288-13.293
52. Perigaud C., Aubertin A.M., Benzaria S., Pelicano H., Girardet J.L., Maury G., Gosselin G., Kirn A., and Imbach J.L. Equal inhibition of the replication of human immunodeficiency virus in human T-cell culture by ddA bis(SATE)phosphotriester and 3′-azido-2′,3′ dideoxythymidine. Biochem. Pharmacol. 48 (1994) 11-14
53. Perno C.F., Aquaro S., Rosenwirth B., Balestra E., Peichl P., Billich A., Villani N., and Caliò R. In vitro activity of inhibitors of late stages of the replication of HIV in chronically infected macrophages. J. Leukocyte Biol. 56 (1994) 381-386
54. Perno C.F., Bergamini A., Pesce C.D., Milanese G., Capozzi M., Aquaro S., Thaisrivongs S., Tarpley W.G., Zon G., D'Agostini C., Rocchi G., Garaci E., and Calio' R. Inhibition of the protease of human immunodeficiency virus blocks replication and infectivity of the virus in chronically infected macrophages. J. Infect. Dis. 168 (1993) 1148-1156
55. Perno C.F., Newcomb F.M., Davis D.A., Aquaro S., Humphrey R.W., Calio' R., and Yarchoan R. Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus. J. Infect. Dis. 178 (1998) 413-422
56. Perno C.F., Yarchoan R., Cooney D.A., Hartman N.R., Webb D.S., Hao Z., Mitsuya H., Johns D.G., and Broder S. Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2′,3′-dideoxynucleosides. J. Exp. Med. 168 (1988) 1111-1125
57. Pollicita M., Ruff M., Polianova M., Pert C., Ranazzi A., Perno C.F., and Aquaro S. Anti-HIV-1 and anti-apoptotic effects of d-Ala-Peptide T-Amide in human macrophages and in a neuronal cell line. 13th Conference on Retroviruses and Opportunistic Infection. Denver, February 5-8 (2006)
58. Price R.W., Palmatier R., Wring S., Lu J., Baker B., Sailstad J., Lollo N., Spudich S., Hoh R., Liegler T., Miralles D., Kuritzkes D., and Deeks S. Enfuvirtide cerebrospinal fluid pharmacokinetics: a potential tool to analyze CSF HIV origin and the therapeutic role of local drug penetration. 121st Conference on Retroviruses and Opportunistic Infection. Boston, February 22-25 (2005)
59. Puech F., Gosselin G., Lefebvre I., Pompon A., Aubertin A.M., Kirn A., and Imbach J.L. Intracellular delivery of nucleoside monophosphates through a reductase-mediated activation process. Antiviral Res. 22 (1993) 155-174
60. Reeves J.D., Gallo S.A., Ahmad N., Miamidian J., Harvey P.E., Sharron M., Pöhlmann S., Sfakianos J.N., Derdeyn C.A., Blumenthal R., Hunter E., and Doms R.W. Sensivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Microbiology 99 (2003) 16249-16254
61. Reeves J.D., and Piefer A.J. Emerging drug targets for antiretroviral therapy. Drugs 65 (2005) 1747-1766
62. Ruff M.R., Melendez-Guerrero L.M., Yang Q.E., Ho W.Z., Mikovits J.W., and Pert C.B. Peptide T inhibits HIV-1 infection mediated by the chemokine receptor-5 (CCR5). Antiviral Res. 52 (2001) 63-75
63. Ruff M.R., Polianova M., Pert C.B., and Ruscetti F.W. Update on d-Ala-Peptide T-Amide (DAPTA): a viral entry inhibitor that blocks CCR5 chemokine receptors. Curr. HIV Res. 1 (2003) 51-67
64. Sadler B.M., Hanson C.D., Chittick G.E., Symonds W.T., and Roskell N.S. Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults. Antimicrob. Agents Chemother. 43 (1999) 1686-1692
65. Shi B., De Girolami U., He J., Wang S., Lorenzo A., Busciglio J., and Gabuzda D. Apoptosis induced by HIV-1 infection of the central nervous system. J. Clin. Invest. 98 (1996) 1979-1990
66. Strizki J.M., Tremblay C., Xu S., Wojcik L., Wagner N., Gonsiorek W., Hipkin R.W., Chou C.C., Pugliese-Sivo C., Xiao Y., Tagat J.R., Cox K., Priestley T., Sorota S., Huang W., Hirsch M., Reyes R.G., and Baroudy B.M. Discovery and characterization of vicriviroc (SCH 417690) A CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 49 (2005) 4911-4919
67. Tschachler E., Groh V., Popovic M., Mann D.L., Konrad K., Safai B., Eron L., Di Marzo Veronese F., Wolff K., and Stingl G. Epidermal Langerhans cells a target for HTLV-III/LAV infection. J. Invest. Dermatol. 88 (1987) 233-237
68. Tuttle D.L., Harrison J.K., Anders C., Sleasman J.W., and Goodenow M.M. Expression of CCR5 increases during monocyte differentiation and directly mediates macrophage susceptibility to infection by human immunodeficiency virus type 1. J. Virol. 72 (1998) 4962-4969
69. Tyor W.R., Power C., Gendelman H.E., and Markham R.B. A model of human immunodeficiency virus encephalitis in scid mice. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 8658-8662
70. Wang J., Roderiquez G., Oravecz T., and Norcross M.A. Cytokine regulation of human immunodeficiency virus type 1 entry and replication in human monocytes/macrophages through modulation of CCR5 expression. J. Virol. 72 (1998) 7642-7647
71. Wasmuth J.C., Nischalke H.D., Jutte A., Fatkenheuer G., Salzberger B., Sauerbruch T., Spengler U., Rockstroh J.K., and Dumoulin F.L. Chemokine mRNA levels in mononucleated cells of HIV-infected patients before and after initiation of PI- versus NNRTI-containing HAART. Antiviral Res. 61 (2004) 207-212
72. Weissman D., Rabin R.L., Arthos J., Rubbert A., Dybul M., Swofford R., Venkatesan S., Farber J.M., and Fauci A.S. Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor. Nature 389 (1997) 981-985
73. Westby M., and Van der Ryst E. CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection. Antivir. Chem. Chemother. 16 (2005) 339-354
74. Willey S., Peters P.J., Sullivan W.M., Dorr P., Perros M., and Clapham P.R. Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: effects of viral diversity, target cell and receptor density. Antiviral Res. 68 (2005) 96-108